New drug hope for GPA patients with stubborn ENT symptoms
Disease control
Not yet recruiting
This study tests whether adding TAVNEOS to standard treatment helps control ear, nose, and throat symptoms in people with granulomatosis with polyangiitis (GPA). About 30 adults with active ENT disease will receive either TAVNEOS or a placebo for 52 weeks. The goal is to see if m…
Phase: PHASE2, PHASE3 • Sponsor: Robert Spiera, MD • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC